Skip to main content
SpringerLink
Log in

Therapeutic Resistance in Leukemia

  • Chapter
Cancer Drug Resistance

Part of the book series: Cancer Drug Discovery and Development ((CDD&D))

Abstract

At Southern Research Institute, a series of in vivo drug-resistant murine P388 leu-kemias were developed for use in the evaluation of crossresistance and collateral sensitivity. These in vivo models have been used for the evaluation of new compounds of potential clinical interest. Crossresistance data coupled with knowledge of the mechanisms of resistance operative in the drug-resistant leukemias may identify useful guides for patient selection for clinical trials of new anti tumor drugs and noncrossresistant drug combinations.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Weinstein HJ, Tarbell NJ. Leukemias and lymphomas of childhood. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2001:2235–2256.

    Google Scholar 

  2. Bloomfield CD, Caligiuri MA. Molecularbiology of leukemias. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2001:2389–2404.

    Google Scholar 

  3. Scheinberg DA, Maslak P, Weiss M. Acute leukemias. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2001:2404–2433.

    Google Scholar 

  4. Kantarjian HM, Faderl S, Talpaz M. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2001:2433–2447.

    Google Scholar 

  5. Schabel FM Jr, Skipper HE, Trader MW, Laster WR Jr, Griswold DP Jr, Corbett TH. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 1983; 67:905–922 (see correction, Cancer Treat Rep 1984; 68:453-459).

    PubMed  Google Scholar 

  6. Waud WR, Griswold DP Jr. Therapeutic resistance in leukemia. In: Teicher B A, ed., Drug resistance in oncology. New York: Marcel Dekker, 1993:227–250.

    Google Scholar 

  7. Johnson RK, Howard WS. Development and cross-resistance characteristics of a subline of P388 leukemia resistant to 4′-(9-acridinylamino)methanesulfon-m-anisidide. Eur J Cancer Clin Oncol 1982; 18:479–487.

    Article  PubMed  CAS  Google Scholar 

  8. Johnson RK, Broome MG, Howard WS, Evans SF, Pritchard DF. Experimental therapeutic and biochemical studies of anthracenedione derivatives. In: Rozencweig M, Von Hoff DD, Staquet MJ, eds. New anticancer drugs: mitoxantrone and bisantrene. New York: Raven, 1983:1–28.

    Google Scholar 

  9. Eng WK, McCabe FL, Tan KB, et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 1990; 38:471–480.

    PubMed  CAS  Google Scholar 

  10. Burchenal JH, Kalaher K, Dew K, Lokys L, Gale G. Studies of cross-resistance, synergistic combinations and blocking activity of platinum derivatives. Biochimie 1978; 60:961–965.

    Article  CAS  Google Scholar 

  11. Rose WC, Huftalen JB, Bradner WT, Schurig JE. In vivo characterization of P388 leukemia resistant to mitomycin C. In Vivo 1987; 1:47–52.

    CAS  Google Scholar 

  12. Sladek NE, Landkamer GJ. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines. Cancer Res 1985; 45:1549–1555.

    PubMed  CAS  Google Scholar 

  13. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984; 44:5156–5160.

    PubMed  CAS  Google Scholar 

  14. Harrison SD Jr, Brockman RW, Trader MW, Laster WR Jr, Griswold DP Jr. Cross-resistance of drug-resistant murine leukemias to deoxy spergualin (NSC 356894) in vivo. Invest New Drugs 1987; 5:345–351.

    Article  PubMed  CAS  Google Scholar 

  15. Redwood WR, Colvin M. Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 1980; 40:1144–1149.

    PubMed  CAS  Google Scholar 

  16. Suzukake K, Petro BJ, Vistica DT. Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 1982; 31:121–124.

    Article  PubMed  CAS  Google Scholar 

  17. Kraker AJ, Moore CW. Accumulation of cis-diamminedichloroplatinum(II) and platinum analogues by platinum-resistant murine leukemia cells in vitro. Cancer Res 1988; 48:9–13.

    PubMed  CAS  Google Scholar 

  18. Kraker AJ, Moore CW. Elevated DNA polymerase beta activity in a cis-diamminedichloroplatinum(II) resistant P388 murine leukemia cell line. Cancer Lett 1988; 38:307–314.

    Article  PubMed  CAS  Google Scholar 

  19. Catapano CV, Broggini M, Erba E, et al.In vitro and in vivomethazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res 1987; 47:4884–4889.

    PubMed  CAS  Google Scholar 

  20. Gorbacheva LB, Kukushkina GV, Durdeva AD, Ponomarenko NA. In vivo DNA damage and resistance to 1-methyl-1-nitrosourea and 1,3-bis(2-chloroethyl)-1-nitrosourea in L1210 leukemia cells. Neoplasma 1988; 35:3–14.

    PubMed  CAS  Google Scholar 

  21. Kobayashi E, Okabe M, Kono M, et al. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C. Cancer Chemother Pharmacol 1993; 32:20–24.

    Article  PubMed  CAS  Google Scholar 

  22. Mandelbaum-Shavit F, Ramu A. Dihydrofolate reductase activity in adriamycin and methotrexate sensitive and resistant P388 leukemia cells. Cell Biol Int Rep 1987; 11:389–396.

    Article  PubMed  CAS  Google Scholar 

  23. Fichtner I, Stein U, Hoffmann J, Winterfeld G, Pfeil D, Hentschel M. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immuno-genicity. Anticancer Res 1994; 14:1995–2004.

    PubMed  CAS  Google Scholar 

  24. Sirotnak FM, Moccio DM, Kelleher LE, Goutas LJ. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate-resistant L1210 clonal cell lines derived in vivo. Cancer Res 1981; 41:4447–4452.

    PubMed  CAS  Google Scholar 

  25. Goldie JH, Krystal G, Hartley D, Gudauskas G, Dedhar S. A methotrexate insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells. Eur J Cancer 1980; 16:1539–1546.

    PubMed  CAS  Google Scholar 

  26. Dolnick BJ, Berenson RJ, Bertino JR, Kaufman RJ, Nunberg JH, Schimke RT. Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178Y cells. J Cell Biol 1979; 83:394–402.

    Article  PubMed  CAS  Google Scholar 

  27. Cowan KH, Jolivet J. A novel mechanism of resistance to methotrexate in human breast cancer cells: lack of methotrexate polyglutamate formation. Clin Res 1983; 31:508A.

    Google Scholar 

  28. Tezuka M, Sugiyama H, Tamemasa O, Inaba M. Biochemical characteristics of a 5-fluorouracil-resis-tant subline of P388 leukemia. Gann 1982; 73:70–76.

    PubMed  CAS  Google Scholar 

  29. Mulkins MA, Heidelberger C. Biochemical characterization of fluoropyrimidine-resistant murine leu-kemic cell lines. Cancer Res 1982; 42:965–973.

    PubMed  CAS  Google Scholar 

  30. Brockman RW. Mechanisms of resistance. In: Sartorelli AC, Johns DG, eds. Handbook of experimental pharmacology. New series. Vol 38/1. New York: Springer, 1974:352–410.

    Google Scholar 

  31. Curt GA, Clendeninn NJ, Chabner BA. Drug resistance in cancer. Cancer Treat Rep 1984; 68:87–99.

    PubMed  CAS  Google Scholar 

  32. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 1970; 30:1174–1184.

    PubMed  CAS  Google Scholar 

  33. Deffie AM, Alam T, Seneviratne C, et al. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and p-glycoprotein in cloned cell lines of adriamycin-sensitive and-resistant P388 leukemia. Cancer Res 1988; 48:3595–3602.

    PubMed  CAS  Google Scholar 

  34. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and-resistant P388 leukemia cell lines. Cancer Res 1989; 49:58–62.

    PubMed  CAS  Google Scholar 

  35. McPherson JP, Brown GA, Goldenberg GJ. Characterization of a DNA topoisomerase II alpha gene rearrangement in adriamycin-resistantP388 leukemia: expression of a fusion messenger RNA transcript encoding topoisomerase II alpha and the retinoic acid receptor alpha locus. Cancer Res 1993; 15:5885–5889.

    Google Scholar 

  36. Per SR, Mattern MR, Mirabelli CK, Drake FH, Johnson RK, Crooke ST. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Mol Pharmacol 1987; 32:17–25.

    PubMed  CAS  Google Scholar 

  37. Tan KB, Mattern MR, Eng WK, McCabe FL, Johnson RK. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst 1989; 81:1732–1735.

    Article  PubMed  CAS  Google Scholar 

  38. Kessel D, Wheeler C, Chou T-H, Howard WS, Johnson RK. Studies on a mode of resistance to m-AMSA. Biochem Pharmacol 1982; 31:3008–3010.

    Article  PubMed  CAS  Google Scholar 

  39. Harker WG, Slade DL, Dalton WS, Meltzer PS, Trent JM. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein over-expression. Cancer Res 1989; 49:4542–4549.

    PubMed  CAS  Google Scholar 

  40. Kamath N, Grabowski D, Ford J, Kerrigan D, Pommier Y, Ganapathi R. Overexpression of P-glycoprotein and alterations in topoisomerase II in P388 mouse leukemia cells selected in vivo for resistance to mitoxantrone. Biochem Pharmacol 1992; 44:937–945.

    Article  PubMed  CAS  Google Scholar 

  41. Higashigawa M, Ido M, Ohkubo T, et al. Increased sensitivity to 1-β-D-arabinofuranosylcytosine in P388 murine leukemic cells resistant to etoposide. Leuk Res 1989; 13:39–42.

    Article  PubMed  CAS  Google Scholar 

  42. Waud WR, Vasanthakumar G, Schmid SM, et al. Characterization of an in vivo murine P388 leukemia resistant to etoposide. Proc Am Assoc Cancer Res 1992; 33:453.

    Google Scholar 

  43. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41:1967–1972.

    PubMed  CAS  Google Scholar 

  44. Inaba M, Nagashima K, Sakurai Y. Cross-resistance of vincristine-resistant sublines of P388 leukemia to mitoxantrone with special emphasis on the relationship between in vitro and in vivo cross-resistance. Gann 1984; 75:625–630.

    PubMed  CAS  Google Scholar 

  45. McGrath T, Center MS. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 1988; 48:3959–3963.

    PubMed  CAS  Google Scholar 

  46. Tsuruo T, Oh-Hara T, Saito H. Characteristics of vincristine resistance in vincristine resistant human myelogenous leukemia K562. Anticancer Res 1986; 6:637–641.

    PubMed  CAS  Google Scholar 

  47. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003; 3:1–19.

    Article  PubMed  CAS  Google Scholar 

  48. Schabel FM Jr, Griswold DP Jr, Laster WR Jr, Corbett TH, Lloyd HH. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol Ther 1977; 1:411–435.

    CAS  Google Scholar 

  49. Lloyd HH. Application of tumor models toward the design of treatment schedules for cancer chemotherapy. In: Drewinko B, Humphrey RM, eds. Growth kinetics and biochemical regulation of normal and malignant cells. Baltimore: Williams & Wilkins, 1977:455–469.

    Google Scholar 

  50. Dykes DJ, Waud WR. Murine L1210 and P388 leukemias. In: Teicher B, ed., Tumor models in cancer research. Totowa: Humana Press, 2002:23–40.

    Google Scholar 

  51. Ho AD, Seither E, Ma DDF, Prentice G. Mitoxantrone-induced toxicity and DNA strand breaks in leukemic cells. Br J Haematol 1987; 65:51–55.

    PubMed  CAS  Google Scholar 

  52. Nelson EM, Tewey KM, Liu LF. Mechanisms of antitimor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4′-(9-acridinylamino)methanesulfon-m-anisidide. Proc Natl Acad Sci US A 1984; 81:1361–1365.

    Article  CAS  Google Scholar 

  53. Johnson RK, Chitnis MP, Embrey WM, Gregory EB. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia. Cancer Treat Rep 1978; 62:1535–1547.

    PubMed  CAS  Google Scholar 

  54. Schabel FM Jr, Trader MW, Laster WR Jr, Corbett TH, Griswold DP Jr. cis-Dichlorodiammine-platinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63:1459–1473.

    PubMed  CAS  Google Scholar 

  55. Jong S de, Timmer-Bosscha H, Vries EGE de, Mulder NH. Increased topoisomerase II activity in a cisplatin resistant cell line. Proc Am Assoc Cancer Res 1990; 31:337.

    Google Scholar 

  56. Danks MK, Yalowich JC, B0eck WT. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res 1987; 47:1297–1301.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Therapeutics, Southern Research Institute, Birmingham, AL

    William R. Waud PhD

Authors
  1. William R. Waud PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Genzyme Corporation, Framingham, MA

    Beverly A. Teicher PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Waud, W.R. (2006). Therapeutic Resistance in Leukemia. In: Teicher, B.A. (eds) Cancer Drug Resistance. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-035-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-035-5_7

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-530-9

  • Online ISBN: 978-1-59745-035-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation